A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene

Acta Dermato-Venereologica

Volumn 83, Issue 4, 2003, Pages 277-281

  Bayerl, Christiane ^a,b   Schwarz, Beate ^a   Jung, Ernst G ^a  

^a UNIVERSITY OF MANNHEIM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical trial; Melanocytic naevi; Ultraviolet

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; PLACEBO; RETINOIC ACID;

ADULT; ARM; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRY SKIN; DYSPLASTIC NEVUS; FEMALE; FLU LIKE SYNDROME; FOLLICULITIS; FOOT; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTOSIS; LONG TERM CARE; LYMPH NODE METASTASIS; MALE; MELANOCYTIC NEVUS; MELANOMA; MENSTRUAL IRREGULARITY; METASTASIS; NEVUS; PITYRIASIS ROSEA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SIDE EFFECT; SKIN DISCOLORATION; SKIN SCALING; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TREATMENT FAILURE; ULTRAVIOLET RADIATION; VERTIGO;

ADMINISTRATION, ORAL; ADULT; BETA CAROTENE; DOUBLE-BLIND METHOD; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0042671156     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310016535     Document Type: Article

References (35)

1. Elder DE, Greene MH, Guerry D, Kraemer KH, Clark WH. The dysplastic nevus syndrome: our definition. Am J Dermatopathol 1982; 4: 455-460.
2. Ackermann AB, Mihari I. Dysplasia, atypical melanocytes, dysplastic nevi, the dysplastic nevus syndrome and the relationship of dysplastic nevi to malignant melanoma. Hum Pathol 1985; 16: 87-91.
3. Augustsson A, Stierner U, Rosdahl I, Suurkula M. Melanocytic naevi in sun-exposed and protected skin in melanoma patients and controls. Acta Derm Venereol 1991; 71: 512-517.
4. Nguyen TD, Siskind V, Green L, Frost C, Green A. Ultraviolet radiation, melanocytic naevi and their dose-response relationship. Br J Dermatol 1997; 137: 91-95.
5. Jung EG. Photocarcinogenesis of the skin. J Dermatol 1991; 18: 1-10.
6. Breitbart M, Garbe C, Büttner P, Weiß J, Soyer HP, Stocker U, et al. Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. Acta Derm Venereol 1997; 77: 374-378.
7. Biesalski HK, Obermueller-Jevic UC. UV light, beta-carotene and human skin: beneficial and potentially harmful effects. Arch Biochem Biophys 2001; 389: 1-6.
8. Black HS. Prooxidant and anti-oxidant mechanisms of BHT and beta carotene on photocarcinogenesis. Front Biosci 2002; 7: 1044-1055.
9. Mathews-Roth MM. Beta-carotene therapy for erythropoetic protoporphyria and other photosensitivity diseases. Biochimie 1986; 68: 875-884.
10. Stahl W, Sies H. Carotenoids and protection against solar UV radiation. Skin Pharmacol Appl Skin Physiol 2002; 15: 291-291.
11. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary β-carotene materially reduce human cancer rates? Nature 1981; 290: 201-208.
12. Karagas MR, Greenberg ER, Nierenberg D, Stukel TA, Mooris JS, Stevens MM, et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha-tocopherol, beta-carotene, and retinol: a nested case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 25-29.
13. Wald NJ, Thompson SG, Densem JW, Boreham J, Bailey A. Serum beta-carotene and subsequent risk of cancer: results from the BUPA study. Br J Cancer 1998; 57: 428-433.
14. Armitage P. Statistical methods in medical research. New York: John Wiley, 1971.
15. Augustsson A, Stierner U, Suurkula M, Rosdahl I. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991; 124: 152-156.
16. Bataille V, Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffith K, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73: 1605-1611.
17. Hofmann-Wellenhof R, Soyer HP, Wolff IH, Smolle J, Reischle S, Rieger E, et al. Ultraviolet radiation of melanocytic nevi. A dermoscopic study. Arch Dermatol 1998; 134: 845-850.
18. Fuller CJ, Faulkner H, Bendich A, Parker RS, Roe DA. Effect of β-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. Am J Clin Nutr 1992; 56: 684-690.
19. Gollnik HPM, Hopfenmüller W, Hemmes C, Chung SC, Schmid C, Sundermeier K, et al. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UV sunlight: results of the Berlin-Eilath study. Eur J Dermatol 1996; 6: 200-205.
20. Wolf C, Steiner A, Hönigsmann H. Do oral carotenoids protect human skin against ultraviolet erythema, psoralen phototoxicity, and ultraviolet-induced DNA damage? J Invest Dermatol 1988; 90: 55-57.
21. Grob JJ, Bastuji-Garin S, Vaillant L, Rojeau JC, Bernard P, Sassolas B, et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol 1996; 107: 694-697.
22. Noonan FP, Webber LJ, De Fabo EC, Hoffmann HA, Bendich A, Mathews-Roth M. Dietary beta carotene and ultraviolet-induced immunosuppression. Clin Exp Immunol 1996; 103: 54-60.
23. Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987; 107: 409-501.
24. Bollag W. Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumours. Int Z Vitaminforsch 1970; 40: 299-314
25. Levine N, Meyskens FL Jr. Topical vitamin A acid therapy for cutaneous metastatic melanoma. Lancet 1980; 2: 224-273.
26. Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol 1990; 126: 494-499.
27. Edwards L, Meyskens FL Jr, Levine NS. The effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol 1989; 20: 257-260.
28. Potter JD. Beta-carotene and the role of intervention studies. Cancer Lett 1997; 114: 329-331.
29. Omenn GS, Goodman GE, Thorquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
30. The alpha-tocopherol, beta carotene cancer prevention study group: the effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
31. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahiti M, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560-1570.
32. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
33. Truscott TG. β-Carotene and disease: a suggested prooxidant and anti-oxidant mechanism and speculations concerning its role in cigarette smoking. J Photochem Photobiol 1996; 35: 233-235.
34. Stahl W, Heinrich U, Jungmann H, Tronnier H, Sies H. Carotenoids in human skin: noninvasive measurement and identification of dermal carotenoids and carotenol esters. Methods Enzymol 2000; 319: 494-502.
35. Green A, Willimas G, Neale R, Leslie D, Parsons P, Marks GC, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354: 723-729.